A Phase 1 interventional study of Rituximab and Rituximab in Lymphoma, Follicular, sponsored by Hoffmann-La Roche. Completed at 62 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.
Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 29th largest by enrollment of the 188 interventional ones that give a count, is one of 14 that started in 2009, is one of 27 in phase 1, and was the 115th registered.
1,893 studies on the registry are indexed under Lymphoma, Follicular; 290 are open to participants now.
Browse Lymphoma, Follicular studies →12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–75
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 129 · Phase 3 37
First in 1997; this study’s year is marked. 14 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 281 is above the median of 48 across 1,505 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 48 across the 188 interventional studies. Of the 150 that completed or were terminated, 75 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 194 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
22 studies in Lymphoma, Follicular by Hoffmann-La Roche: none open now, 2 under way, 1 of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 22 studies in Lymphoma, Follicular by Hoffmann-La Roche, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2009, is one of 2 in phase 1, and was the 2nd registered.
Hoffmann-La Roche’s Lymphoma, Follicular studies by the year they started, since 2004.
5 of the studies testing rituximab in Lymphoma, Follicular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04224493Phase 3Epizyme, Inc.A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | 2027-02-13 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT06471738Chinese PLA General HospitalCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | 2026-12-30 |
| NCT01473628M.D. Anderson Cancer CenterRadiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma | 2027-05-20 |
| NCT04998669Juan P. Alderuccio, MDLoncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 194 studies testing rituximab in Lymphoma, Follicular, from their registry updates:
Among Hoffmann-La Roche’s 22 in Lymphoma, Follicular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This 2 stage study will compare the pharmacokinetics and safety profile of subcutaneous and intravenous rituximab in participants with follicular lymphoma. In the first stage, participants who have achieved at least a partial response after induction treatment with intravenous rituximab will be randomized to one of 3 treatment cohorts, to receive rituximab 375 milligram per square meter (mg/m\^2) intravenously, 375 mg/m\^2 subcutaneously or 625 mg/m\^2 subcutaneously, and pharmacokinetics evaluated on an ongoing basis. Upon selection of the subcutaneous dose (800 mg/m\^2) which results in rituximab trough plasma concentration (C trough) values comparable to those achieved with the intravenous formulation, participants in the second stage of the study will be randomized to receive either the subcutaneous or intravenous formulation to demonstrate comparability of the C trough levels with both routes of administration. Maintenance therapy will continue every 2 or 3 months with the subcutaneous formulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rituximab
Drug: Rituximab
Drug: Rituximab
Drug: Rituximab
Drug: Rituximab
Drug: Rituximab
Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
Rituximab subcutaneous injection at 800 mg/m\^2 dose level, administered every 2 or 3 months.
Also known as: MabThera/Rituxan
Rituximab subcutaneous injection 625 mg/m\^2 administered every 2 or 3 months.
Also known as: MabThera/Rituxan
Rituximab intravenous infusion 375 milligram per square meter (mg/m\^2) administered every 2 or 3 months.
Also known as: MabThera/Rituxan
Rituximab subcutaneous injection 375 mg/m\^2 administered every 2 or 3 months.
Also known as: MabThera/Rituxan
Minimum Observed Plasma Trough Concentration (C trough)
Time frame: Up to 29 months
Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau)
Time frame: Up to 29 months
Maximum Observed Plasma Concentration (Cmax)
Time frame: Up to 29 months
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Up to 29 months
Plasma Decay Half-Life (t1/2)
Time frame: Up to 29 months
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
Time frame: Up to 29 months
The record gives a start of Sep 2009, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab